Clinical Trials Logo

Leukemia clinical trials

View clinical trials related to Leukemia.

Filter by:

NCT ID: NCT02014558 Completed - Clinical trials for Acute Myeloid Leukemia

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Start date: October 9, 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study was to assess the safety and tolerability, including the maximum tolerated dose, of gilteritinib in participants with relapsed or treatment-refractory acute myeloid leukemia (AML). This study also determined the pharmacokinetic (PK) parameters of gilteritinib.

NCT ID: NCT02013648 Completed - Clinical trials for Acute Myeloid Leukemia (AML)

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycelâ„¢)

Start date: July 2014
Phase: Phase 3
Study type: Interventional

This is a randomized phase III open-label, multicenter trial evaluating standard induction therapy (daunorubicin [DNR] and cytarabine [Ara-C]) and consolidation therapy (high-dose cytarabine [HDAC]) with or without dasatinib in adult patients with newly diagnosed CBF-AML

NCT ID: NCT02011945 Completed - Clinical trials for Chronic Myeloid Leukemia

A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia

Start date: February 7, 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find a dose of Nivolumab that can be safely added to Dasatinib in patients with Chronic Myeloid Leukemia.

NCT ID: NCT02010931 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients

Start date: September 2013
Phase:
Study type: Observational

A retrospective analysis of historical data looking at relapse free survival and overall survival rates in adult philadelphia negative B-pre-cursor acute lymphoblastic leukemia patients.

NCT ID: NCT02007863 Completed - Leukemia Clinical Trials

Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia

Start date: August 2008
Phase: N/A
Study type: Interventional

Unrelated Cord Blood (UCB) transplant in children is a viable stem cell transplant modality for patients with leukemia and myelodysplasia. UCB is now considered "Standard Of Care" in cases where a suitable living bone marrow donor is not available. The survival of UCB is similar to Matched Unrelated Marrow Transplant. This study is considered "Research" since UCB is not a licensed product and requires investigational new drug (IND). THERE ARE NO SPECIFIC RESEARCH QUESTIONS IN THIS PROTOCOL. This protocol merely provides UCB as a stem cell treatment modality to pediatric patients who may require it after a conditioning regimen that excludes Total Body Irradiation.

NCT ID: NCT02005471 Completed - Clinical trials for Chronic Lymphocytic Leukemia

A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

MURANO
Start date: March 17, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this open-label, multicenter, randomized, Phase III study is to evaluate the benefit of venetoclax in combination with rituximab compared with bendamustine in combination with rituximab in participants with relapsed or refractory CLL. Participants will be randomly assigned in 1:1 ratio to receive either venetoclax + rituximab (Arm A) or bendamustine + rituximab (Arm B).

NCT ID: NCT02004522 Completed - Clinical trials for Chronic Lymphocytic Leukemia

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

Start date: November 2013
Phase: Phase 3
Study type: Interventional

A Phase 3 clinical trial to examine the efficacy of duvelisib monotherapy versus ofatumumab monotherapy in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).

NCT ID: NCT02003612 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia

Start date: October 1, 2013
Phase:
Study type: Observational

A retrospective analysis of historical data looking at hematological remission and survival in adult relapsed / refractory B-precursor acute lymphoblastic leukemia patients.

NCT ID: NCT02000427 Completed - Clinical trials for Relapsed/Refractory Philadelphia Positive B-precursor ALL

Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia

Start date: January 3, 2014
Phase: Phase 2
Study type: Interventional

The primary objective is to evaluate the rate of complete remission/complete remission with partial hematological recovery (CRh*) in adults with relapsed/refractory Philadelphia chromosome positive (Ph+) B-precursor acute lymphoblastic leukemia (ALL) who receive blinatumomab.

NCT ID: NCT01999556 Completed - Clinical trials for Leukemia, Myelogenous, Acute

LCI-HEM-SPEC-001: Tissue Collection for Genetic Analysis of Acute Myelogenous Leukemia

Start date: November 2013
Phase:
Study type: Observational

The purpose of this study is to obtain high quality specimens for molecular studies for the identification and characterization of genetic mutations involved in the pathogenesis of familial myeloid malignancies. Specimens obtained will be de-identified, linked to basic clinical data, and sent to Washington University (Division of Oncology, St. Louis, MO) for molecular analyses. Some specimens sent to Washington University may also be used for quality control analyses.